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Patients with medically unexplained symptoms (MUS)
have little or no demonstrable disease explanation for
the symptoms, and comorbid psychiatric disorders are
frequent. Although common, costly, distressed, and
often receiving ill-advised testing and treatments, most
MUS patients go unrecognized, which precludes effec-
tive treatment. To enhance recognition, we present an
emerging perspective that envisions a unitary classifi-
cation for the entire spectrum of MUS where this
diagnosis comprises severity, duration, and comorbid-
ity. We then present a specific approach for making the
diagnosis at each level of severity. Although our disease-
based diagnosis system dictates excluding organic
disease to diagnose MUS, much exclusion can occur
clinically without recourse to laboratory or consultative
evaluation because the majority of patients are mild.
Only the less common, “difficult” patients with moder-
ate and severe MUS require investigation to exclude
organic diseases. By explicitly diagnosing and labeling
all severity levels of MUS, we propose that this diagnos-
tic approach cannot only facilitate effective treatment
but also reduce the cost and morbidity from unneces-
sary interventions.
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P
atients with medically unexplained symptoms (MUS), also
called somatization, represent one of the most common
conditions in medicine.
1–3 We define MUS as those physical
symptoms having little or no basis in underlying organic
disease;
4 when organic disease exists, the symptoms are
inconsistent with or out of proportion to it.
5 We caution that
people with MUS are not necessarily abnormal. Many exhibit it
but seldom or never seek care.
6 MUS becomes a medical issue
when it leads to health care–seeking for feared but nonexistent
physical illness.
7,8
The prevalence of all MUS in the outpatient setting is
reported from 25% to 75%, and pain is the most common
type,
1–3 i.e., on average, approximately one-half or more of all
outpatientshavelittleornophysicaldiseaseexplanationfortheir
symptoms. Consistent with this, Kroenke and Mangelsdorf
found, among all new symptoms, that only 16% had an organic
disease basis.
9
Limited evidence suggests that treatment in primary care
and specialty settings is effective, but MUS patients seldom
receive it.
10,11 They first must be recognized and diagnosed. In
addition to lack of treatment, inadequate identification occa-
sions safety and cost problems: ill-advised lab testing and “trial
treatments” can lead to iatrogenic complications and increased
costs.
12–16 To facilitate diagnosis, we present an emerging
consensus that proposes a unitary diagnostic classification
system of MUS.
4,17–24 We also review the diagnostic approach
it requires.
CURRENT WAYS TO CLASSIFY MUS
Psychiatric Nosology—DSM-IV
Table 1 summarizes the criteria for the 7 DSM-IV Somatoform
Disorders.
18 The only validated entities, somatization disorder
(SD) and conversion disorder, are infrequent.
18,20,25–33 The
failure to validate the other DSM-IVentities stems from extensive
overlap of criteria.
34 An abridged SD (ASD) construct requires
fewer symptoms and is more comprehensive, but it also lacks
validation.
26,35 Multi-Somatoform Disorder (MSD)
36–38 defines
MUS patients of similar severity,
39 and its reliability and validity
presently are under investigation.
36,38,40,41
MUS Patients Without a DSM-IV Diagnosis
Consistent with others,
4,26,42 Smith, Gardiner, and collea-
gues demonstrated in 206 distressed, high-utilizing MUS
patients that less than 25% had any DSM-IV Somatoform
Disorders (4.4%) or ASD (18.9%). Nonetheless, 60.2% had
nonsomatoform (“psychiatric”) diagnoses, primarily anxiety
and depression.
23 This study’s gold standard definition of
MUS came from a reliable, physician-conducted chart re-
view.
23,43 The “DSM-negative” patients were less psychologi-
cally and physically distressed than those with DSM-IV
Somatoform diagnoses or ASD, but they were more distressed
than the normal ones. Because researchers have relied
almost entirely on DSM as the gold standard for MUS, these
large numbers of distressed DSM-negative patients have been
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685completely overlooked by the field.
43 An earlier study identi-
fied some of these patients as “minor acute illness” (MAI) to
highlight minor, transient symptoms that differ from the 41
in DSM-IV.
44
In low-utilizing MUS patients, most symptoms in primary
care resolve spontaneously and permanently. For example, a
prospective study of 500 ambulatory clinic patients showed
that 70% improved after 2 weeks and that this improvement
was sustained after 3 months.
45,46
Medical MUS Syndromes
In medical settings, chronic MUS patients typically are under-
stood as “difficult”
47 or as one of several named MUS condi-
tions, e.g., Chronic Fatigue Syndrome, Irritable Bowel
Syndrome, Fibromyalgia. These also lack validity because of
overlapping criteria.
21
PROPOSED CLASSIFICATION OF MUS
Many have favored an approach that lumps all “MUS” patients
into 1 category, and other names have been suggested, e.g., “MUS
Spectrum Disorder” or “Physical Symptom Disorder”.
4,17–24
Table 2 provides a template and supporting data for an evolving
unitary or continuum model, and it identifies where the categor-
ical disease entities fall on the spectrum of MUS.
In summarizing this classification, we also have been guided
by Klinkman, Coyne, and colleagues who identified 3 param-
eters for classifying depression, and we have applied them to
MUS: severity, duration, and comorbidity.
48–51 In this contin-
uum or dimensional model, SD is at the very severe end,
whereas ASD and MSD also are labeled severe. Those who do
not resemble DSM-IV entities (DSM-negative; Minor Acute
Illness) are in the moderate range of the spectrum, merging
into mild and normal MUS patients when health care–seeking
and psychological distress decrease.
Extrapolating from many
9,46,52, we estimate in Table 2 that
∼80% of all MUS patients in a clinical setting are “mild”: acute
symptoms, low utilization, respond to reassurance and reso-
lution of stressors, and present little difficulty for providers.
Although often receiving much testing, they typically are not
recognized as MUS at all; they are viewed, for example, as
“noise in the system.” The remaining 20% of MUS patients are
high utilizers, which vary from subacute to chronic, and exist
on the severity spectrum from “moderate” to “severe.” This
group features the physical disability and severe psychological
problems that command most of our clinical attention, the
ones providers usually think of as somatization, MUS, or the
“difficult” patient.
Comorbid organic and psychiatric diseases are common
across the entire severity spectrum, but psychological dys-
function and psychiatric diagnoses increase as the MUS
becomes more severe,
53 as do functional disability and job-
lessness,
26,54 a history of physical or sexual abuse,
55–57 and
prescription and nonprescription substance misuse.
58–60 In
primary care patients with SD, 10 psychiatric problems were
more prevalent than in the general population, in the order of
decreasing prevalence: depression, anxiety, phobia, panic, alco-
hol abuse, obsessive-compulsive, antisocial personality, schizo-
phrenia, cognitive impairment, and mania.
61 Some posit that
personality disorders in general are comorbid conditions.
57,62
DIAGNOSIS OF MUS
MUS can be diagnosed only by excluding organic diseases.
18,63
After that, clinicians also can make DSM-IV Somatoform
diagnoses or ASD—or one of the named syndromes such as
IBS.
Our focus on excluding organic diseases does not preclude
the possibility of underlying, explanatory psychophysiological
changes,
64 nicely summarized recently for IBS,
65 nor does it
preclude that improved understanding in the future could provide
organic disease explanations for what we now call MUS.
28
Nevertheless, with our present universally applied, disease-based
classification system, the only useful, broadly applicable way to
d i a g n o s eM U Sp a t i e n t si st oe x c l u d eo r g a n i cd i s e a s e .O u rl o n g -
range goal, however, continues to be integrating psychosocial and
biomedical aspects to produce the biopsychosocial diagnoses
articulated by Engel over a quarter of a century ago.
29,66,67
Bespeaking our progress toward biopsychosocial medicine, the
isolated-disease focus needed for diagnosis does not apply to
treatment because psychosocial factors already are demonstrably
key elements in successful medical treatment.
11,68,69
We recommend the following clinical guidelines to exclude
organic diseases.
Normal to Mild MUS. The label “normal to mild” reflects the
infrequent, appropriate seeking of reassurance for worrisome
symptoms, a normal illness behavior.
70 Symptoms may be of
any type and intensity but usually are few and mild, and they
seldom require much laboratory or other diagnostic
investigation. Rather, excluding organic diseases occurs
primarily by history and physical examination and by follow-
Table 1. DSM-IV Somatoform Disorders
Somatization disorder is of many years duration, begins before age 30,
is more common in women, and has (over a lifetime) at least four pain
symptoms, two gastrointestinal symptoms, one sexual symptom, and
one pseudoneurological symptom.
Undifferentiated somatoform disorder, the vast majority of persistent
somatizers, is a residual category for patients who do not meet criteria
for other somatoform disorders, is of at least 6 months duration, has
no gender or age limit, and has at least one symptom.
Conversion disorder usually occurs acutely and lasts about 2 weeks
but may be recurring or chronic, is most frequent in women before
age 35, and exhibits one or more motor, sensory, or seizure
(pseudoneurological) symptoms.
Pain disorder occurs at any age, more often in women, usually is
chronic and persistent, and has one or more pain symptoms that are
the predominant focus of the presentation and that are not restricted
to dyspareunia.
Hypochondriasis occurs at any age in males and females, may be more
common in early adulthood, is at least 6 months duration and often
chronic and persistent, and has one or more symptoms that provoke
an unwarranted fear (which is not delusional or restricted to concerns
about appearance) of organic disease even after reassurance and
appropriate investigation.
Body dysmorphic disorder begins in adolescence, occurs in males and
females equally, is chronic and persistent, and is suggested by
preoccupation with an alleged defect in appearance that causes
patients to feel ugly (anorexia nervosa is classified elsewhere); when
of delusional intensity, an additional diagnosis of delusional disorder,
somatic type is made.
Somatoform disorder not otherwise specified includes disorders with
somatoform symptoms that do not meet the above criteria, such as
pseudocyesis and symptoms of less than 6 months duration.
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44 Making mild MUS explicit as a
diagnosis can help resolve the problem of excessive laboratory
testing, unnecessary treatments, and iatrogenic complica-
tions.
12–16 When symptoms do not follow the expected acute
clinical course (prompt resolution), an organic disease or moder-
ate MUS with incipient high utilization is considered.
Moderate MUS. Moderate MUS also can have symptoms of any
type and intensity, but this newly recognized group exhibits
much greater psychological and physical distress and
utilization than those with normal to mild MUS.
23 Each
episode of symptoms tends to be self-limited over a few weeks
to months, but these patients exhibit high utilization during
this symptomatic period and with recurrences of the same or a
different episode, the subsequent episode often clearing
completely as well; some, however, have chronic, low-grade
symptoms—and merge into the next category. Initially, after a
careful history and physical examination, observation over time
sufficestoexcludeorganicdiseases.Nevertheless,withfrequent
recurrences or chronicity and increased utilization, diagnostic
work-up to exclude organic disease usually is needed.
Severe MUS. In contrast to moderate MUS, severe MUS is
characterized by more bothersome and persistent physical
symptoms (more often of the type found in DSM-IV), still
greater utilization, and more physical and psychological
dysfunction. These patients require definitive laboratory or
consultative investigation or both to exclude organic diseases in
many instances—but only if not already performed
6,20,35,71
and if not resolved by the initial history and physical
examination (H & P) where a diagnosis sometimes can be
established without further investigation, e.g., a clinical
Table 2. The Clinical Spectrum of MUS*
Normal to mild
∼80%
9,46,52
Moderate ∼15% Severe ∼5% Very severe
† <1%
Common name “Worried well” DSM-negative;
MAI
ASD; MSD SD
Utilization‡ Low
9 High
23,44 High
3 High
3,91,92
Age of onset Any Any Any <30 years
18
Specific physical
symptoms
Any Any From DSM symptom list of 41
(ASD) or 15 (MSD)
18,39
41 specific symptoms in DSM-IV
from 4 areas: Pain, GI, sexual,
neurological
18
Body systems
involved
Any Any Musculoskeletal, GI, nervous,
or ill-defined systems
93,94
Musculoskeletal, GI, nervous,
or ill-defined systems
93,94
Symptom
duration
95‡
“Acute” days to
weeks
“Subacute” <6
mos.
“Chronic” >6 mos
18,39 “Chronic” >6 mos
18
Number of
symptoms‡
Few Any >3 (men) & >5 (women) for
ASD
35,96
>7
18
Symptoms occur
and recur with
external stress
and clear when
it abates
95‡
Yes Yes, but recur
frequently
No, but worsen with stress No, but worsen with stress
Depression,
anxiety, dysthymia,
and other psychiatric
problems‡
? 20%
23,97,98 67%
35 88–99%
61,99
Personality
structure
“Normal”
? Personality disorder
98,100 61–72% Personality disorder
101,102;
rarely, psychotic
Prevalence,
community
∼100%
6,103 ? 4.4–22%
20,25–27,35,104 0.03–0.7%
18,20,25–27
Prevalence, all
outpatients
?? 33%
3 5–7%
3,92
Prevalence,
inpatients
?? ? 9%
91
Prevalence,
outpatients
with >5
visits per year
? 51% had MAI
44 14% (includes very severe)
44§
MUS = medically unexplained symptoms; MAI = minor acute illness (derived from chart rating); DSM = Diagnostic and Statistical Manual of Mental
Disorders; ASD = abridged somatization disorder; MSD = Multi-Somatoform Disorder; SD = somatization disorder; GI = gastrointestinal.
*Comorbid medical disease is frequent throughout the spectrum; psychiatric disease also is prevalent, but increases with increasing severity and
utilization in MUS.
†Because there are many data on SD, a separate column (“Very severe”) has been included, although SD is very rare.
‡After organic disease is excluded, these areas particularly lend themselves to the quantification needed for explicit, concrete criteria for MUS subtyping,
e.g., an average of 15 visits yearly over many years with 8 MUS symptoms during the last year that are chronic in a patient with severe depression =
SEVERE; an average of 8 visits/year for the last 24 months for 5 MUS symptoms that occur intermittently but are becoming regularly persistent in a
depressed patient = MODERATE; an average of 2 visits yearly for many years for 2 or 3 MUS symptoms that always occur in relationship to stress and
abate with its resolution in a non-depressed patient = MILD. These examples highlight the proposed need for research to provide specific criteria for each
sub-category of MUS, e.g., cutoff points for number of symptoms, number of visits, and the degree of depression.
§This study did not separate severe and very severe.
?Areas where data are unavailable and where research is particularly needed.
687 Smith and Dwamena: Medically Unexplained Symptoms JGIMdiagnosis of angina. The H & P, of course, also provides the
guidance that specifies which lab tests to order.
72 Because of
the frequent presence of serious current or lifetime psychiatric
disorder, one also makes sure that the diagnostic process itself
does not frighten an already distressed patient. Making a clear,
definitive diagnosis of moderate/severe MUS is essential: it
leads the provider to the next-step—treatment
11—rather than
repetition of testing and consultation in a few months for
persisting symptoms.
Moderate and severe MUS patients require work-up, even
with prominent psychological complaints and without classical
textbook criteria for disease, because there is a high prevalence
(prior probability) of underlying organic diseases.
5 Patients with
chronic low back pain, even with no objective neurological
signs, usually require MRI, CT, or myelography to exclude
impending neurological compromise, infection, or tumor.
71,73
For example, 1 study showed clinically significant disease
(beyond the common uncomplicated disc protrusion and
degenerative changes) in 15%.
74 The sensitivity and specificity
of clinical findings, except for sciatica, are not sufficient to
exclude significant organic diseases in chronic low back pain.
75
Similarly, 35% of patients with chronic abdominal pain or
altered bowel habits or both, the symptoms alone suggesting
IBS, had underlying organic disease explanations.
76 Investiga-
tion (e.g., colonoscopy) is indicated before one can diagnose
thesepatientsasMUS
77,especiallythoseover45yearsofage.
78
Chronic pelvic pain is often thought to be caused by MUS
because of prominent psychological symptoms and a negative
physical exam. But, from 41% to 75% of these women have
organic disease explanations, such as endometriosis, adhe-
sions, and chronic pelvic inflammatory disease,
79–81 and lapa-
roscopy usually is recommended.
79–83
We note that recognizing some organic diseases may still not
lead to success in difficult-to-treat conditions such as endo-
metriosis, and that severe chronic organic diseases, especially
those with pain, can lead to illness behaviors similar to those
found in chronic MUS patients.
68,84,85
The following illustrate the pitfalls of relying on symptoms
alone to make a diagnosis of moderate and severe MUS.
Physical symptom criteria alone (the Rome Criteria) for the
diagnosis of IBS show a sensitivity of 0.85 and a specificity of
only 0.71 when gastrointestinal (GI) symptoms (e.g., bloating,
diarrhea) are used to distinguish IBS from organic dis-
eases.
77,78,86 In another study, 1 of 3 of all organic diseases
and one-half of patients with active peptic ulcer were missed
using clinical symptom criteria alone.
87 Involving 11,366
patients, a review of 15 studies of upper GI symptoms
concluded that physical symptoms did not distinguish be-
tween nonorganic (MUS) and organic diseases.
88
Psychological symptom criteria alone did not distinguish IBS
from those with subsequently proven organic diseases in a
prospective study of patients with abdominal pain and altered
bowel habits.
76 Both groups had similarly elevated psycholog-
ical symptom scores compared to healthy population normals.
Therefore, psychosocial symptoms could not be expected to
differentiate them. These data can be predicted by the
biopsychosocial model
66, which tells us that psychosocial
factors are indeed ubiquitous among organic and nonorganic
(MUS) patients.
85
Table 3 provides several examples demonstrating how the
proposed diagnostic classification might look.
Differential Diagnosis
Rare organic diseases (such as Wilson’s Disease), or those with
vague or unusual presentations (such as multiple sclerosis,
Lyme disease, and porphyria), or those that may have prom-
inent psychological symptoms (such as some with carcinoma
of the pancreas, subdural hematoma, or ulcerative colitis) may
be misdiagnosed as MUS if the physician does not have an
appropriate index of suspicion.
MUS also must be distinguished from 2 rare psychiatric
disorders: factitious disorder (FD) and malingering. For the
sole purpose of assuming the sick role (lack external incen-
tives), patients with FD intentionally produce organic disease,
the Munchausen Syndrome being an extreme example, or they
feign psychological symptoms. Unlike MUS, patients with FD
usually have obvious organic diseases, although the self-
induction itself may not be recognized initially, e.g., bleeding
secondary to surreptitious anticoagulant ingestion or fever
Table 3. Examples of MUS
Case 1—the most common: mild MUS
A 32-year-old man with controlled hypertension presented with the
new onset of fatigue and distracting headaches, and he mentioned the
threat of being laid off work. Physical examination was negative, and
you empathized, supported, reassured, ordered no tests, and
recommended ibuprofen. He reported 2 weeks later the symptoms
had cleared, and that he was back to work.
DIAGNOSIS—MUS
Severity—mild
Duration—acute
Comorbidity—essential hypertension
Case 2—less common: moderate MUS
A 44-year-old woman presented with yet another episode of low back
pain without radicular symptoms. Her diabetes also was poorly
controlled, and she had gained weight. The pain interfered with
work, and she had been in the clinic with recurrences 7 times in the
preceding 12 months. She was not enjoying her life and said that she
had difficulty sleeping, but did not feel depressed. Physical exam
revealed no neurologic deficits and mild paraspinal muscle spasm.
You obtained an MRI of the spine that provided no explanation for the
pain (small disc without neurologic compromise), and you implemented
a program of treatment for her MUS and depression,
10,11 advised
exercise and weight control, and increased her metformin dose.
DIAGNOSIS—MUS
Severity—moderate
Duration—subacute
Comorbidity—depression and poorly controlled diabetes mellitus
Case 3—least common: severe MUS
A 50-year-old man related a long history of severe neck pain and
headaches, virtually constant over the last 5 years. He wanted a “new
approach” because he was “not getting better,” even though he went
to 4 doctors and 2 pain clinics in the last year. His COPD was
somewhat worse recently as well. He denied depression but did have
anhedonia (lack of enjoyment), insomnia, difficulty concentrating,
and weight gain over the preceding year. Physical exam was negative
except for changes of COPD. You did not repeat the neck and brain
MRI his previous doctor had obtained 3 months earlier but reviewed it
with the radiologist and learned that several minor abnormalities (a
few white matter changes and mild disc protrusion without neurologic
compromise) were unrelated to his symptoms. You initiated treatment
for his MUS and depression
10,11 and advised a short trial of
antibiotics for his COPD.
DIAGNOSIS—MUS
Severity—severe
Duration—chronic
Comorbidity—depression, COPD
688 Smith and Dwamena: Medically Unexplained Symptoms JGIMcaused by self-injection of feces. FD patients feigning psychi-
atric illness, however, are much more difficult to differentiate.
Malingering patients do not induce organic diseases, but
they feign or grossly exaggerate physical or psychological
symptoms for some external incentive such as financial
compensation or obtaining drugs. MUS patients do not
intentionally produce or feign their symptoms and usually do
not have obvious external incentives.
A much more common primary care differential diagnosis
occurs when a patient known to have significant organic
disease develops MUS around the same symptoms and thus
poses a difficult diagnostic problem,
63 e.g., the patient with a
recent myocardial infarction who now complains daily of chest
pain. After investigation to ensure stability, the physician often
is able to restrict further study.
Equally troublesome, how does one determine whether a
known MUS patient develops an organic disease? It has been
proposed that when a symptom represents a new organic
disease, the patient will present in a clearly different way.
5,89,90
If the physician carefully listens to and briefly examines the
patient for objective evidence of disease, a significant organic
disease seldom is overlooked.
5
CONCLUSIONS AND RECOMMENDATIONS
To maximize care and understanding, an emerging perspective
indicates that MUS be classified according to: (1) severity,
ranging from mild → moderate → severe; (2) duration, where
most MUS patients will be acute (and mild), but the most
difficult ones will be subacute and chronic (moderate and
severe); and (3) comorbidity, psychiatric or medical or both.
History and physical examination and observation over time
suffice to make the diagnosis, by excluding organic diseases, in
∼80% of MUS patients. These “mild” patients have a few acute
visits and little ongoing physical or psychological distress.
Conversely, ∼20% of patients, classified as “moderate” or
“severe,” have increased utilization for subacute/chronic
symptoms and are more physically and psychologically dis-
tressed. They typically require laboratory evaluation to exclude
organic diseases and make a diagnosis of MUS.
MUS is largely untreated, common and costly, and attended
by considerable distress and morbidity—some iatrogenic.
Because improved recognition/diagnosis can ameliorate these
problems, we recommend convening a group of experts to
develop research-based, consensus definitions for each sub-
type of the MUS spectrum. Whereas the symptom and
utilization parameters cannot themselves exclude organic
diseases to diagnose MUS, they can be used to subclassify its
3 dimensions. The mild, moderate, and severe categories, we
propose, must be more concretely defined, analogous to DSM
criteria, if we are to maximize their potential for better defining
treatment and prognosis at all levels of MUS. Only with
explicit, agreed-upon criteria, for all their shortcomings, can
the field move ahead. Finally, we suggest that the consensus
group, at some point, include patients and work jointly with
them to develop a nonpejorative name for MUS.
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